Skip to main content Skip to search
A Pilot Study to Evaluate the Feasibility of Individualized Yoga for Inpatient Children Receiving Intensive Chemotherapy
BMC complementary and alternative medicine
Short Title: BMC Complement.Altern.Med.
Format: Journal Article
Publication Date: Nov 30, 2014
Pages: 2 - 015-0529-3
Sources ID: 40566
Notes: LR: 20161215;; JID: 101088661; 0 (Antineoplastic Agents); 2014/02/05 00:00 [received]; 2015/01/16 00:00 [accepted]; 2015/01/25 06:00 [entrez]; 2015/01/27 06:00 [pubmed]; 2015/05/15 06:00 [medline]; epublish
Visibility: Public (group default)
Abstract: (Show)
BACKGROUND: Fatigue is an important problem in paediatric cancer patients and yoga may be an effective intervention. The primary objective was to determine the feasibility of individualized yoga for hospitalized children receiving intensive chemotherapy. METHODS: We included English-speaking children and adolescents aged 7-18 years receiving intensive chemotherapy or haematopoietic stem cell transplantation (HSCT). Yoga was conducted three times weekly for three weeks. The primary outcome was feasibility, defined as ability to deliver at least 60% of planned sessions. Secondary outcomes were parent-reported Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale, Fatigue Scale-Parent, PedsQL Generic Core Scales and PedsQL Acute Cancer Module. RESULTS: Between January and October 2013, 11 patients were enrolled. Median age was 14.0 (range 7.7-16.4) years and 6 (55%) were boys. Yoga was feasible with 10/11 participants meeting the threshold for feasibility. The median number of yoga sessions was 9 (range 3-13). No adverse events were attributed to yoga. Mean+/-standard deviation for the day 21 proxy-reported PedsQL general fatigue scores was 55.6+/-15.5. Qualitative comments suggested design changes for future yoga studies. CONCLUSIONS: Individualized yoga is feasible for inpatient children receiving intensive chemotherapy. Future work will include development and conduct of a randomized trial for fatigue amelioration. TRIAL REGISTRATION: NCT02105389.